Nina Niu Sanford Shared NOM-3 Study Results
Nina Niu Sanford, Assistant Professor and Chief of Gastrointestinal Radiation Oncology at Harvard/Brigham and Women’s Hospital/Massachusetts General Hospital, shared a post on X about a paper by Agnieszka Żółciak-Siwińska et al. published in the Radiotherapy and Oncology:
“Short course RT > FOLFOX x 3 > brachy (10Gy x 2) in T2-T4, small N+ rectal cancer.
Organ pres 53%, ~OPRA but << OPERA, likely due to T4 and lower brachy dose.
Brachy can achieve Complete Response with less chemo for lower risk patients, but operator dependent, resource-limited, and trials smaller/heterogeneous.”
Title: Endorectal high-dose-rate brachytherapy boost in rectal cancer: Results of the prospective cohort NOM-3 study on the watch-and-wait strategy
Authors: Agnieszka Żółciak-Siwińska, Lucyna Pietrzak, Ewa Wrońska, Anna Hołdakowska, Aleksandra Kapała, Leszek Zając, Marek Szczepkowski, Karol Paciorek, Bartłomiej Skrzypiec, Wojciech Michalski, Joanna Socha, Krzysztof Bujko
You can read the Full Article in the Radiotherapy and Oncology.
More posts featuring Nina Niu Sanford on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023